Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study
CONCLUSION: Patients with GCA/PMR were more likely to have severe COVID-19 and higher mortality compared to those with RA. This worse prognosis is mostly due to well known risk factors for the general population rather than vasculitis per se.PMID:35926375 | PMC:PMC9296684 | DOI:10.1016/j.jaut.2022.102868 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - August 4, 2022 Category: Allergy & Immunology Authors: Matheus Vieira Clo é Comarmond Julien Labreuche Adrien Mirouse David Saadoun Christophe Richez Ren é-Marc Flipo Eric Hachulla Elodie Drumez Patrice Cacoub FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Source Type: research

Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature
CONCLUSIONS: Early clinical suspicion is key to guarantee maximum response of treatment.PMID:35926472 | DOI:10.1016/j.ejpn.2022.07.002 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - August 4, 2022 Category: Neurology Authors: Sarai Urtiaga Valle Sarah Souvannanorath Nicolas Leboucq Stephanie Haouy Fran çois Rivier Agathe Roubertie Pierre Meyer Source Type: research

Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

Rituximab Administered for Recurrent Membranous Nephropathy in a Kidney Transplant Recipient Did Not Eliminate Donor-Specific Antibodies
We describe a case of a renaltransplantrecipient with recurrent membranous nephropathy and recent development of donor-specific antibodies but without histological evidence of active antibody-mediated rejection. The patient received 3 weekly doses of rituximab for recurrent membranous nephropathy, and complete remission was achieved. One year after, he has preserved an excellentrenal function without proteinuria. However, repeated measurements of donor-specific antibodies revealed that rituximab only modestly reduced donor-specific antibodies. Donor-specific antibody levels remained considerably higher than the laboratory ...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - August 4, 2022 Category: Transplant Surgery Authors: Myrto Giannopoulou Katerina Tarassi Glykeria Tsouka Christalleni Christodoulidou Ioannis Stefanidis Theodoros Eleftheriadis Source Type: research

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
Rapidly progressive (RP) interstitial lung disease (ILD) is a life-threatening complication of juvenile dermatomyositis (JDM); however, it is generally refractory to treatment; to the best of our knowledge, no... (Source: Pediatric Rheumatology)
Source: Pediatric Rheumatology - August 4, 2022 Category: Rheumatology Authors: Kentaro Nishi, Masao Ogura, Naotaka Tamai, Naofumi Gima, Kentaro Ide, Goro Koinuma, Koichi Kamei and Shuichi Ito Tags: Case Report Source Type: research

Paraneoplastic syndromes: A focus on pathophysiology and supportive care
CONCLUSION: Supportive care for PNSs lends opportunities to pharmacists to add quality, value, and safety.PMID:35916756 | DOI:10.1093/ajhp/zxac211 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - August 2, 2022 Category: Drugs & Pharmacology Authors: Clement Chung Emily Allen Godsfavour Umoru Source Type: research

How I Treat Rituximab in the Frail and Elderly with Severe ANCA-Associated Glomerulonephritis
Clin J Am Soc Nephrol. 2022 Aug 2:CJN.04760422. doi: 10.2215/CJN.04760422. Online ahead of print.NO ABSTRACTPMID:35918105 | DOI:10.2215/CJN.04760422 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Silke Brix Vladim ír Tesař Source Type: research

Paraneoplastic syndromes: A focus on pathophysiology and supportive care
CONCLUSION: Supportive care for PNSs lends opportunities to pharmacists to add quality, value, and safety.PMID:35916756 | DOI:10.1093/ajhp/zxac211 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - August 2, 2022 Category: Drugs & Pharmacology Authors: Clement Chung Emily Allen Godsfavour Umoru Source Type: research

How I Treat Rituximab in the Frail and Elderly with Severe ANCA-Associated Glomerulonephritis
Clin J Am Soc Nephrol. 2022 Aug 2:CJN.04760422. doi: 10.2215/CJN.04760422. Online ahead of print.NO ABSTRACTPMID:35918105 | DOI:10.2215/CJN.04760422 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Silke Brix Vladim ír Tesař Source Type: research

How I Treat Rituximab in the Frail and Elderly with Severe ANCA-Associated Glomerulonephritis
Clin J Am Soc Nephrol. 2022 Aug 2:CJN.04760422. doi: 10.2215/CJN.04760422. Online ahead of print.NO ABSTRACTPMID:35918105 | DOI:10.2215/CJN.04760422 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Silke Brix Vladim ír Tesař Source Type: research

How I Treat Rituximab in the Frail and Elderly with Severe ANCA-Associated Glomerulonephritis
Clin J Am Soc Nephrol. 2022 Aug 2:CJN.04760422. doi: 10.2215/CJN.04760422. Online ahead of print.NO ABSTRACTPMID:35918105 | DOI:10.2215/CJN.04760422 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 2, 2022 Category: Urology & Nephrology Authors: Silke Brix Vladim ír Tesař Source Type: research